158 related articles for article (PubMed ID: 28284831)
1. PLGA implants: How Poloxamer/PEO addition slows down or accelerates polymer degradation and drug release.
Hamoudi-Ben Yelles MC; Tran Tan V; Danede F; Willart JF; Siepmann J
J Control Release; 2017 May; 253():19-29. PubMed ID: 28284831
[TBL] [Abstract][Full Text] [Related]
2. Improving the therapeutic efficacy of prilocaine by PLGA microparticles: Preparation, characterization and in vivo evaluation.
Bragagni M; Gil-Alegre ME; Mura P; Cirri M; Ghelardini C; Di Cesare Mannelli L
Int J Pharm; 2018 Aug; 547(1-2):24-30. PubMed ID: 29800738
[TBL] [Abstract][Full Text] [Related]
3. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Desai KG; Mallery SR; Schwendeman SP
Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
[TBL] [Abstract][Full Text] [Related]
4. Effect of Particle Size on Drug Loading and Release Kinetics of Gefitinib-Loaded PLGA Microspheres.
Chen W; Palazzo A; Hennink WE; Kok RJ
Mol Pharm; 2017 Feb; 14(2):459-467. PubMed ID: 27973854
[TBL] [Abstract][Full Text] [Related]
5. Impact of the experimental conditions on drug release from parenteral depot systems: From negligible to significant.
Delplace C; Kreye F; Klose D; Danède F; Descamps M; Siepmann J; Siepmann F
Int J Pharm; 2012 Aug; 432(1-2):11-22. PubMed ID: 22569229
[TBL] [Abstract][Full Text] [Related]
6. How autocatalysis accelerates drug release from PLGA-based microparticles: a quantitative treatment.
Siepmann J; Elkharraz K; Siepmann F; Klose D
Biomacromolecules; 2005; 6(4):2312-9. PubMed ID: 16004477
[TBL] [Abstract][Full Text] [Related]
7. In-situ forming composite implants for periodontitis treatment: How the formulation determines system performance.
Do MP; Neut C; Metz H; Delcourt E; Mäder K; Siepmann J; Siepmann F
Int J Pharm; 2015; 486(1-2):38-51. PubMed ID: 25791762
[TBL] [Abstract][Full Text] [Related]
8. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.
Desai KG; Mallery SR; Schwendeman SP
Eur J Pharm Biopharm; 2008 Sep; 70(1):187-98. PubMed ID: 18472254
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of sustained-release clonidine-loaded PLGA microparticles.
Gaignaux A; Réeff J; Siepmann F; Siepmann J; De Vriese C; Goole J; Amighi K
Int J Pharm; 2012 Nov; 437(1-2):20-8. PubMed ID: 22903047
[TBL] [Abstract][Full Text] [Related]
10. Unintended potential impact of perfect sink conditions on PLGA degradation in microparticles.
Klose D; Delplace C; Siepmann J
Int J Pharm; 2011 Feb; 404(1-2):75-82. PubMed ID: 21056644
[TBL] [Abstract][Full Text] [Related]
11. Development of zolmitriptan loaded PLGA/poloxamer nanoparticles for migraine using quality by design approach.
Girotra P; Singh SK; Kumar G
Int J Biol Macromol; 2016 Apr; 85():92-101. PubMed ID: 26724690
[TBL] [Abstract][Full Text] [Related]
12. In-situ forming PLGA implants for intraocular dexamethasone delivery.
Bode C; Kranz H; Siepmann F; Siepmann J
Int J Pharm; 2018 Sep; 548(1):337-348. PubMed ID: 29981408
[TBL] [Abstract][Full Text] [Related]
13. In-situ forming PLGA implants: Towards less toxic solvents.
Ramos F; Willart JF; Neut C; Agossa K; Siepmann J; Siepmann F
Int J Pharm; 2024 May; 657():124121. PubMed ID: 38621617
[TBL] [Abstract][Full Text] [Related]
14. Improved small molecule drug release from in situ forming poly(lactic-co-glycolic acid) scaffolds incorporating poly(β-amino ester) and hydroxyapatite microparticles.
Fisher PD; Palomino P; Milbrandt TA; Hilt JZ; Puleo DA
J Biomater Sci Polym Ed; 2014; 25(11):1174-93. PubMed ID: 24903524
[TBL] [Abstract][Full Text] [Related]
15. Polymer degradation induced drug precipitation in PLGA implants - Why less is sometimes more.
Zlomke C; Barth M; Mäder K
Eur J Pharm Biopharm; 2019 Jun; 139():142-152. PubMed ID: 30902733
[TBL] [Abstract][Full Text] [Related]
16. Design and characterisation of new nanoparticulate polymer blends for drug delivery.
Csaba N; González L; Sánchez A; Alonso MJ
J Biomater Sci Polym Ed; 2004; 15(9):1137-51. PubMed ID: 15503631
[TBL] [Abstract][Full Text] [Related]
17. Preparation, characterization and in vitro cytotoxicity of indomethacin-loaded PLLA/PLGA microparticles using supercritical CO2 technique.
Kang Y; Wu J; Yin G; Huang Z; Yao Y; Liao X; Chen A; Pu X; Liao L
Eur J Pharm Biopharm; 2008 Sep; 70(1):85-97. PubMed ID: 18495445
[TBL] [Abstract][Full Text] [Related]
18. PLGA-based monolithic filaments prepared by hot-melt extrusion: In-vitro comparative study.
Kamel R; Abbas H
Ann Pharm Fr; 2018 Mar; 76(2):97-106. PubMed ID: 29145995
[TBL] [Abstract][Full Text] [Related]
19. Enhanced encapsulation and bioavailability of breviscapine in PLGA microparticles by nanocrystal and water-soluble polymer template techniques.
Wang H; Zhang G; Ma X; Liu Y; Feng J; Park K; Wang W
Eur J Pharm Biopharm; 2017 Jun; 115():177-185. PubMed ID: 28263795
[TBL] [Abstract][Full Text] [Related]
20. PLGA-based microparticles loaded with bacterial-synthesized prodigiosin for anticancer drug release: Effects of particle size on drug release kinetics and cell viability.
Obayemi JD; Danyuo Y; Dozie-Nwachukwu S; Odusanya OS; Anuku N; Malatesta K; Yu W; Uhrich KE; Soboyejo WO
Mater Sci Eng C Mater Biol Appl; 2016 Sep; 66():51-65. PubMed ID: 27207038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
